|
Janux Therapeutics, Inc. (Janx) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Janux Therapeutics, Inc. (JANX) Bundle
Diseñada para la precisión, nuestra calculadora DCF (JANX) le permite evaluar la valoración de Janux Therapeutics, Inc. utilizando datos financieros del mundo real, ofreciendo una flexibilidad completa para modificar todos los parámetros esenciales para las proyecciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 3.6 | 8.6 | 8.1 | 10.0 | 12.3 | 15.2 | 18.8 | 23.2 |
| Revenue Growth, % | 0 | 0 | 0 | 136.79 | -6.14 | 23.46 | 23.46 | 23.46 | 23.46 | 23.46 |
| EBITDA | -3.8 | -4.8 | -32.8 | -66.3 | -71.0 | -2.0 | -2.5 | -3.0 | -3.8 | -4.6 |
| EBITDA, % | 100 | 100 | -902.28 | -769.28 | -878.68 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .0 | .0 | .1 | .8 | 2.0 | 4.7 | 5.8 | 7.2 | 8.9 | 11.0 |
| Depreciation, % | 100 | 100 | 3.11 | 9.77 | 24.19 | 47.41 | 47.41 | 47.41 | 47.41 | 47.41 |
| EBIT | -3.8 | -4.8 | -32.9 | -67.1 | -73.0 | -2.0 | -2.5 | -3.0 | -3.8 | -4.6 |
| EBIT, % | 100 | 100 | -905.39 | -779.04 | -902.87 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | .7 | 7.8 | 375.0 | 327.0 | 344.0 | 10.0 | 12.3 | 15.2 | 18.8 | 23.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 8.0 | .0 | .0 | .0 | 4.0 | 4.9 | 6.1 | 7.5 | 9.3 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | -.2 | -.7 | .0 | 3.7 | 4.6 | 5.7 | 7.0 | 8.6 |
| Inventories, % | 100 | 100 | -5.5 | -8.13 | 0 | 37.27 | 37.27 | 37.27 | 37.27 | 37.27 |
| Accounts Payable | .3 | .4 | 2.5 | 2.2 | 2.4 | 6.4 | 8.0 | 9.8 | 12.1 | 15.0 |
| Accounts Payable, % | 100 | 100 | 67.58 | 25.07 | 29.99 | 64.53 | 64.53 | 64.53 | 64.53 | 64.53 |
| Capital Expenditure | .0 | .0 | -1.5 | -6.4 | -1.9 | -2.8 | -3.4 | -4.2 | -5.2 | -6.4 |
| Capital Expenditure, % | 100 | 100 | -40.75 | -74.84 | -22.89 | -27.69 | -27.69 | -27.69 | -27.69 | -27.69 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.0 | -3.8 | -32.8 | -57.6 | -73.0 | -1.8 | -2.3 | -2.8 | -3.5 | -4.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3.7 | -11.6 | -24.0 | -63.0 | -73.3 | -3.6 | -.2 | -.2 | -.2 | -.3 |
| WACC, % | 20.88 | 20.87 | 20.88 | 20.87 | 20.88 | 20.88 | 20.88 | 20.88 | 20.88 | 20.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | -9 | |||||||||
| Diluted Shares Outstanding, MM | 44 | |||||||||
| Equity Value Per Share | -0.21 |
What You Will Get
- Real JANX Financial Data: Pre-filled with Janux Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Easily modify key inputs such as revenue growth, WACC, and EBITDA %.
- Automatic Calculations: Instantly see Janux Therapeutics' intrinsic value update based on your adjustments.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for accurate DCF results.
- User-Friendly Design: Intuitive structure and clear instructions suitable for all experience levels.
Key Features
- Innovative Drug Development Pipeline: Focus on unique therapeutic approaches for cancer treatment.
- Robust Clinical Trial Management: Comprehensive tracking and analysis of ongoing clinical studies.
- Customizable Financial Projections: Adjust revenue forecasts, R&D expenses, and market penetration rates.
- Integrated Market Analysis: Evaluate competitive landscape and market opportunities for [JANX].
- Dynamic Reporting Tools: Visual dashboards present key performance indicators for informed decision-making.
How It Works
- Download: Obtain the pre-configured Excel file containing Janux Therapeutics, Inc.'s (JANX) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC as per your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time for accurate insights.
- Test Scenarios: Generate various forecasts and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for Janux Therapeutics, Inc. (JANX)?
- Accurate Data: Utilize real Janux financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from building from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and guided instructions cater to users of all experience levels.
Who Should Use Janux Therapeutics, Inc. (JANX)?
- Investors: Gain insights into innovative cancer therapies with our cutting-edge research and development data.
- Healthcare Analysts: Streamline your analysis with comprehensive reports on our pipeline and market potential.
- Consultants: Easily tailor presentations or reports using our detailed product information and market strategies.
- Biotech Enthusiasts: Enhance your knowledge of breakthrough therapies and their impact on patient care.
- Educators and Students: Utilize our resources as a practical case study in biotechnology and pharmaceutical courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Janux Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Janux Therapeutics, Inc. (JANX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.